Study of the effectiveness of the natural product SALIRAVIRA containing licorice, Cone flower, Ginseng, Hyssop, Rhubarb and Rosemary extracts on the recovery of Covid-19 patients
Determining the effectiveness of the natural product SALIRAVIRA containing of Licorice, Coneflower , Ginseng, Hyssop, Rhubarb and Rosemary extracts as antiviral treatment in COVID-19 patients
Design
Two arm parallel group randomized double-blind controlled trial
Settings and conduct
Patients are recruited in Tehran Heart center and clinic assigned in two parallel groups randomly.Participants and outcome evaluators are blind to the study
Participants/Inclusion and exclusion criteria
Inclusion criteria: Covid-19 infection confirmed by positive PCR-viral load test Some or all of the symptoms include fever, fatigue, muscle aches (headache), headache, cough, chest tightness, and shortness of breath. Exclusion criteria: Malignant tumors and other acute systemic diseases and respiratory problems Life-threatening comorbidity Use of any other herbal substance.Pregnancy Lactation and drug and Alcohol abuse.
Intervention groups
Intervention group: Patients who receive herbal product SALIRAVIRA along with standard treatments. Control group: Patients who receive only standard treatments
Main outcome variables
Virus clearance, Improving the symptoms of the disease such as fever and shortness of breath
General information
Reason for update
Acronym
IRCT registration information
IRCT registration number:IRCT20201220049771N1
Registration date:2020-12-31, 1399/10/11
Registration timing:registered_while_recruiting
Last update:2020-12-31, 1399/10/11
Update count:2
Registration date
2020-12-31, 1399/10/11
Registrant information
Name
Tahereh Hosseinabadi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 8820 0118
Email address
hosseinabadi.t@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-12-21, 1399/10/01
Expected recruitment end date
2021-03-15, 1399/12/25
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Study of the effectiveness of the natural product SALIRAVIRA containing licorice, Cone flower, Ginseng, Hyssop, Rhubarb and Rosemary extracts on the recovery of Covid-19 patients
Public title
study of the effectiveness of the natural product SALIRAVIRA on the treatment of COVID-19 patients
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Covid-19 infection clinical confirmed
Positive PCR-viral load test for COVID-19
People with a history of contact with COVID-19 infected patients in the last 10 days
Lung involvement under 20% - Using CT-Scan
Exclusion criteria:
Pregnancy and Lactation
Malignant tumors and other acute systemic diseases with special indication
Patients suffering from autoimmune diseases like psoriasis ,ALS and MS
Respiratory problems Life-threatening comorbidity
People addicted to alcohol or drugs
Use of any other experimental treatment for Covid 19
Age
From 12 years old to 80 years old
Gender
Both
Phase
2
Groups that have been masked
No information
Sample size
Target sample size:
120
Randomization (investigator's opinion)
Randomized
Randomization description
The participants will be assigned to two groups by block randomization method. In order to minimize the probability of sequence prediction, blocks with variable size (4 and 6) will be used. The randomization ratio will be 1:1. Randomization will be done using Random allocation software.Allocation concealment will be done by assigning unique codes
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of School of Pharmacy and Nursing & Midwifery - Shahid Beheshti University of Medic
Street address
NO 2660, Vali-asr Ave, Tehran
City
Tehran
Province
Tehran
Postal code
1996835113
Approval date
2020-12-13, 1399/09/23
Ethics committee reference number
IR.SBMU.PHARMACY.REC.1399.276
Health conditions studied
1
Description of health condition studied
COVID-19
ICD-10 code
U07.1
ICD-10 code description
COVID-19 virus identified
Primary outcomes
1
Description
Virus Clearance
Timepoint
At the beginning of the study and and 4 and 8 days after intake
Method of measurement
Polymerase chain reaction (PCR)
2
Description
Fever and symptoms
Timepoint
At the beginning of the study and daily during treatment after intake
Method of measurement
Using a thermometer and clinical diagnosis
3
Description
shortness of breath
Timepoint
At the beginning of the study and daily during treatment after intake
Method of measurement
Medical diagnosis
Secondary outcomes
1
Description
olfactory (sense of smell)
Timepoint
At the beginning of the study and daily during treatment after intake
Method of measurement
Questionnaire with interview
2
Description
sense of taste
Timepoint
At the beginning of the study and daily during treatment after intake
Method of measurement
Questionnaire with interview
Intervention groups
1
Description
Intervention group: Patients who receiving herbal product "SALIRAVIRA" containing mentioed extracts orally and as a respiratory spray at the same time with standard treatments: 1- Oral 750 mg SALIRAVIRA tablet containing 500 mg of plant extracts mentioned before; 4 times a day , Once every 6 hours (this pill is packed in blisters contain 10 tablet and will be provided to each patient for the duration of treatment, ie 32 tablet) All process of extraction, production and packaging done under GMP conditions in Mimdaroo pharmaceutical company. 2 - SALIRAVIRA respiratory spray (20ml), which contains plant extracts mentioned before will be used 4 times a day, once every 6 hours, nasally or orally with SALIRAVIRA tablets. SALIRAVIRA spray contains 100mcl of plant extract per puff and its daily dose is 400 mcl based on pharmacopoeia and monographs. All stages of production and packaging of SALIRAVIRA spray have been done under GMP conditions and in Mimdaroo Pharmaceutical company. The duration of treatment will be 8 days.
Category
Treatment - Drugs
2
Description
Control group: Patients receiving standard treatments for COVID-19 disease for 8 days. Standard treatment is determined according to the protocols and guidelines of the Ministry of Health and is performed in all centers.
Category
Treatment - Drugs
Recruitment centers
1
Recruitment center
Name of recruitment center
Tehran Heart Center- infectious disease Dept.
Full name of responsible person
Naser Mohammadi
Street address
North Kargar-Ave
City
Tehran
Province
Tehran
Postal code
1411713138
Phone
+98 21 8802 9600
Email
nasmoh@gmail.com
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Tahereh Hosseinabadi
Street address
No.2660, Vali-e-asr Ave.,Tehran,Iran
City
Tehran
Province
Tehran
Postal code
1996835113
Phone
+98 21 8820 0118
Fax
+98 21 8866 5250
Email
hosseinabadi.t@gmail.com
Web page address
http://pharmacy.sbmu.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Not applicable
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Not applicable
Analytic Code
No - There is not a plan to make this available
Data Dictionary
Not applicable
Title and more details about the data/document
Data can be shared after de-identification
When the data will become available and for how long
Data will be available from April, 2030
To whom data/document is available
Academics employed at various research/university institutions and the industry.
Under which criteria data/document could be used
Using the de-identified data will be allow for scientific research by academics, including faculty members and students. In this case, by sending the request and reviewing it, the requested data will be provided.
From where data/document is obtainable
At first should refer to a person responsible for general inquiries of the clinical trial and then to the principal investigator.
What processes are involved for a request to access data/document
1- The applicant would be asked to provide a written formal request letter, containing the importance of the data . 2- Following the receipt of request letter, the data would be provided in no more than one week.